Production (Stage)
CG Oncology, Inc.
CGON
$25.46
-$0.40-1.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -88.60% | 960.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -88.60% | 960.47% | |||
| Cost of Revenue | 2.49% | 36.58% | |||
| Gross Profit | -4.07% | -34.55% | |||
| SG&A Expenses | 26.35% | 34.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.74% | 35.88% | |||
| Operating Income | -10.92% | -34.47% | |||
| Income Before Tax | -8.35% | -55.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.35% | -55.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.35% | -55.83% | |||
| EBIT | -10.92% | -34.47% | |||
| EBITDA | -10.86% | -34.57% | |||
| EPS Basic | 1.80% | -51.53% | |||
| Normalized Basic EPS | 1.81% | -51.55% | |||
| EPS Diluted | 1.80% | -51.53% | |||
| Normalized Diluted EPS | 1.81% | -51.55% | |||
| Average Basic Shares Outstanding | 10.33% | 2.84% | |||
| Average Diluted Shares Outstanding | 10.33% | 2.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||